Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1956 1
1957 1
1959 1
1960 1
1961 1
1963 1
1964 3
1965 1
1966 1
1967 1
1970 1
1984 2
1985 1
1986 4
1987 6
1988 9
1989 6
1990 12
1991 25
1992 18
1993 44
1994 53
1995 77
1996 80
1997 86
1998 78
1999 87
2000 109
2001 94
2002 75
2003 84
2004 94
2005 110
2006 96
2007 114
2008 151
2009 244
2010 305
2011 375
2012 429
2013 478
2014 483
2015 502
2016 531
2017 492
2018 458
2019 590
2020 586
2021 658
2022 667
2023 686
2024 216

Text availability

Article attribute

Article type

Publication date

Search Results

8,320 results

Results by year

Filters applied: . Clear all
Page 1
KRAS mutation in pancreatic cancer.
Luo J. Luo J. Semin Oncol. 2021 Feb;48(1):10-18. doi: 10.1053/j.seminoncol.2021.02.003. Epub 2021 Feb 23. Semin Oncol. 2021. PMID: 33676749 Free PMC article. Review.
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.
Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P. Kim D, et al. Nature. 2023 Jul;619(7968):160-166. doi: 10.1038/s41586-023-06123-3. Epub 2023 May 31. Nature. 2023. PMID: 37258666 Free PMC article.
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor.
Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ, Hallin J, Laguer J, Lawson JD, Medwid J, Newhouse B, Nguyen P, O'Leary JM, Olson P, Pajk S, Rahbaek L, Rodriguez M, Smith CR, Tang TP, Thomas NC, Vanderpool D, Vigers GP, Christensen JG, Marx MA. Wang X, et al. J Med Chem. 2022 Feb 24;65(4):3123-3133. doi: 10.1021/acs.jmedchem.1c01688. Epub 2021 Dec 10. J Med Chem. 2022. PMID: 34889605 Free article.
KRAS mutation: from undruggable to druggable in cancer.
Huang L, Guo Z, Wang F, Fu L. Huang L, et al. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. doi: 10.1038/s41392-021-00780-4. Signal Transduct Target Ther. 2021. PMID: 34776511 Free PMC article. Review.
The KRAS-G12C inhibitor: activity and resistance.
Liu J, Kang R, Tang D. Liu J, et al. Cancer Gene Ther. 2022 Jul;29(7):875-878. doi: 10.1038/s41417-021-00383-9. Epub 2021 Sep 1. Cancer Gene Ther. 2022. PMID: 34471232
Cancer vaccines: Targeting KRAS-driven cancers.
Zhang Y, Ma JA, Zhang HX, Jiang YN, Luo WH. Zhang Y, et al. Expert Rev Vaccines. 2020 Feb;19(2):163-173. doi: 10.1080/14760584.2020.1733420. Epub 2020 Mar 14. Expert Rev Vaccines. 2020. PMID: 32174221 Review.
Targeting the untargetable KRAS in cancer therapy.
Liu P, Wang Y, Li X. Liu P, et al. Acta Pharm Sin B. 2019 Sep;9(5):871-879. doi: 10.1016/j.apsb.2019.03.002. Epub 2019 Mar 6. Acta Pharm Sin B. 2019. PMID: 31649840 Free PMC article. Review.
KRAS: A Druggable Target in Colon Cancer Patients.
Negri F, Bottarelli L, de'Angelis GL, Gnetti L. Negri F, et al. Int J Mol Sci. 2022 Apr 8;23(8):4120. doi: 10.3390/ijms23084120. Int J Mol Sci. 2022. PMID: 35456940 Free PMC article. Review.
Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Zeissig MN, et al. Trends Cancer. 2023 Nov;9(11):955-967. doi: 10.1016/j.trecan.2023.07.010. Epub 2023 Aug 15. Trends Cancer. 2023. PMID: 37591766 Free article. Review.
8,320 results